Investors Urged to Take Action: Rosen Law Firm Calls for Legal Representation in Elanco Animal Health Securities Class Action
In a critical reminder for investors, Rosen Law Firm—a prominent advocate for investor rights—is urging individuals who purchased securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023, and June 26, 2024, to seek legal representation as an important deadline approaches. Investors have until December 6, 2024, to take action in the pending securities class action lawsuit.
What This Means for Investors
If you acquired Elanco securities during the specified class period, you may be eligible for compensation without any upfront costs. Rosen Law Firm operates on a contingency fee basis, meaning that you only pay legal fees if the case is successful. This approach makes it easier for affected investors to pursue their claims without the burden of out-of-pocket expenses.
How to Participate
For those interested in joining the Elanco class action, the next steps are straightforward. Visit Rosen Law Firm’s website or contact Phillip Kim, Esq. at 866-767-3653 or via email at case@rosenlegal.com for detailed information. A class action lawsuit has already been initiated, and individuals wishing to serve as lead plaintiffs must file a motion with the Court by the December deadline. The lead plaintiff plays a crucial role in managing the litigation and representing the interests of fellow class members.
Why Choose Rosen Law Firm?
Selecting the right legal counsel is vital when pursuing a securities class action. Rosen Law Firm stands out for its extensive experience and proven track record in this field. Unlike many firms that merely serve as intermediaries, Rosen Law actively litigates cases, providing robust representation for its clients.
The firm has garnered global recognition for its dedication to securities class actions and shareholder derivative litigation. Notably, it has achieved significant settlements, including the largest ever in a class action against a Chinese company. In 2017, Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements achieved, and it has consistently ranked among the top four firms since 2013. Over the years, the firm has recovered hundreds of millions of dollars for investors, including more than $438 million in 2019 alone. Laurence Rosen, the firm’s founding partner, has earned accolades as a Titan of the Plaintiffs’ Bar from Law360, with several attorneys receiving honors from Lawdragon and Super Lawyers.
Understanding the Case
The class action lawsuit alleges that Elanco made misleading statements regarding its products during the specified period. Central to the claims are concerns about Zenrelia, a once-daily oral Janus kinase (JAK) inhibitor intended for canine dermatology. The lawsuit contends that Elanco downplayed safety issues and misrepresented the likelihood of obtaining U.S. approval for both Zenrelia and another product, Credelio Quattro, a broad-spectrum parasiticide for dogs. As a result, the company’s public statements about its business and financial outlook were allegedly inflated, leading to significant investor losses when the truth emerged.
As the December deadline approaches, it’s crucial for affected investors to take proactive steps to protect their rights. Engaging with experienced legal counsel like Rosen Law Firm can make a significant difference in navigating the complexities of securities litigation. Don't miss the opportunity to seek justice and potential compensation for your investments.